Labetalol for hypertension in pregnancy

Expert Opinion on Drug Safety

Volumn 14, Issue 3, 2015, Pages 453-461

  Magee, Laura A ^a   Namouz Haddad, Shirin ^b   Cao, Vivien ^a   Koren, Gideon ^b   Von Dadelszen, Peter ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Hypertension; Labetalol; Pre eclampsia; Pregnancy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; DIAZOXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; LABETALOL; METHYLDOPA; NIFEDIPINE; ANTIHYPERTENSIVE AGENT;

ARTICLE; BIRTH DEFECT; BLOOD PRESSURE REGULATION; BRADYCARDIA; BREAST FEEDING; CINAHL; CLEFT LIP; COCHRANE LIBRARY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FIRST TRIMESTER PREGNANCY; HUMAN; HYPOSPADIAS; LIMB REDUCTION DEFECT; MATERNAL HYPERTENSION; MEDLINE; NERVE CELL DIFFERENTIATION; OUTCOME ASSESSMENT; PHARMACOGENOMICS; POLYDACTYLY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINAL DYSRAPHISM; CANADA; FEMALE; HYPERTENSION, PREGNANCY-INDUCED; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREGNANCY OUTCOME; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ANTIHYPERTENSIVE AGENTS; CANADA; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; LABETALOL; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY OUTCOME; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84923339831     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.998197     Document Type: Article

References (87)

1. Frick MH, Porsti P. Combined alphaand beta-adrenoceptor blockade with labetalol in hypertension. Br Med J 1976;1(6017):1046-8
2. Sanders GL, Davies DM, Gales GM, et al. A comparative study of methyldopa and labetalol in the treatment of hypertension. Br J Clin Pharmacol 1979;8(Suppl 2):149S-51S
3. Michael CA. Use of labetalol in the treatment of severe hypertension during pregnancy. Br J Clin Pharmacol 1979;8(Suppl 2):211S-5S
4. Frishman W, Halprin S. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 7. New horizons in beta-adrenoceptor blockade therapy: labetalol. Am Heart J 1979;98(5):660-5
5. Cocco G, Burkart F, Chu D, Foltath F. Intrinsic sympathomimetic activity of beta-adrenoreceptor blocking agents. Eur J Clin Pharmacol 1978;13:1-4
6. Richards DA, Prichard BN. Clinical pharmacology of labetalol. Br J Clin Pharmacol 1979;8(Suppl 2):89S-93S
7. Cannon CM, Levy P, Baumann BM, et al. Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of endorgan damage in the emergency department: a subgroup analysis of the CLUE trial. BMJ Open 2013;3(3):1-7
8. Pugsley DJ, Armstrong BK, Nassim MA, Beilin LJ. Controlled comparison of labetalol and propranolol in the management of severe hypertension. Br J Clin Pharmacol 1976;3(4 Suppl 3): 777-82
9. Fischer JH, Sarto GE, Hardman J, et al. Influence of gestational age and body weight on the pharmacokinetics of labetalol in pregnancy. Clin Pharmacokinet 2014;53(4):373-83
10. Nylund L, Lunell NO, Lewander R, et al. Labetalol for the treatment of hypertension in pregnancy. Pharmacokinetics and effects on the uteroplacental blood flow. Acta Obstet Gynecol Scand Suppl 1984;118:71-3
11. Jeong H, Choi S, Song JW, et al. Regulation of UDPglucuronosyltransferase (UGT) 1A1 by progesterone and its impact on labetalol elimination. Xenobiotica 2008;38(1):62-75
12. Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2012;11:CD002003
13. Kuyper LM, Khan NA. Atenolol vs nonatenolol beta-blockers for the treatment of hypertension: a meta-analysis. Can J Cardiol 2014;30(5 Suppl):S47-53
14. Heran BS, Galm BP, Wright JM. Blood pressure lowering efficacy of alpha blockers for primary hypertension. Cochrane Database Syst Rev 2012;8:CD004643
15. Magee LA, Pels A, Helewa M, on behalf of the Canadian Hypertensive Disorders of Preganncy (HDP) Working Group. Diagnosis, evaluation and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens 2014;4:105-45
16. Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. J Obstet Gynaecol Can 2014;36(5):416-38
17. Society of Obstetric Medicine of Australia and New Zealand (SOMANZ). 2014. Available from: www.somanz.org/guidelines.asp
18. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013;122(5):1122-31
19. National Institute for Health and Clinical Excellence. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. Guidance nice org uk/cg107. 2013
20. Prichard BN, Richards DA. Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. Br J Clin Pharmacol 1979;8(Suppl 2):239S-44S
21. Bateman BT, Hernandez-Diaz S, Huybrechts KF, et al. Patterns of outpatient antihypertensive medication use during pregnancy in a Medicaid population. Hypertension 2012;60(4):913-20
22. Gerard J, Blazquez G, Lardoux H, et al. [Effect of 2 beta-blockers on arterial hypertension during pregnancy. Results of a prospective study on 56 pregnant hypertensive women treated with atenolol and labetalol]. J Gynecol Obstet Biol Reprod (Paris) 1983;12(8):891-900
23. Gerard J, Blazquez G, Mounac M, et al. [Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol]. Rev Fr Gynecol Obstet 1984;79(11):713-17
24. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 9th edition. Lippincott Williams and Wilkins, Philadelphia; 2011
25. Reprotox. Available from: www.reprotox.org [Accessed 21 September 2014]
26. Yakoob MY, Bateman BT, Ho E, et al. The risk of congenital malformations associated with exposure to beta-blockers early in pregnancy: a meta-analysis. Hypertension 2013;62(2):375-81
27. Gillon TER, Pels A, von Dadelszen P, et al. Hypertensive disorders of pregnancy: a systematic review of international cinical practice guidelines. PLoS One 2014;9(12):e113715
28. Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2013;7:CD001449
29. Tavasoli F, Saghafi N, Ghomian N, et al. Comparison of effects of labetalol and hydralazine in treatment of hypertension in patients with severe preeclampsia. Iran J Obstet Gynecol Infertil 2012;15(17):1-7
30. Nederlandse Vereniging voor Obstetrie Gynaecologie (The Dutch Society of Obstetrics and Gynaecology). Hypertensieve aandoeningen in de zwangerschap. 2011. Available from: www.nvog.nl
31. Ashe RG, Moodley J, Richards AM, Philpott RH. Comparison of labetalol and dihydralazine in hypertensive emergencies of pregnancy. S Afr Med J 1987;71(6):354-6
32. Baggio MR, Martins WP, Calderon AC, et al. Changes in fetal and maternal Doppler parameters observed during acute severe hypertension treatment with hydralazine or labetalol: a randomized controlled trial. Ultrasound Med Biol 2011;37(1):53-8
33. Harper A, Murnaghan GA. Maternal and fetal haemodynamics in hypertensive pregnancies during maternal treatment with intravenous hydralazine or labetalol. Br J Obstet Gynaecol 1991;98(5):453-9
34. Mabie WC, Gonzalez AR, Sibai BM, Amon E. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol 1987;70(3 Pt 1):328-33
35. Saudan P, Billieux M-H, Pechere A, et al. Which first-line drug to control severe hypertension in pregnancy? A pilot study. Pregnancy Hypertens 2012;2(3):182
36. Vigil-De GP, Lasso M, Ruiz E, et al. Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2006;128(1-2):157-62
37. Garden A, Davey DA, Dommisse J. Intravenous labetalol and intravenous dihydralazine in severe hypertension in pregnancy. Clin Exp Hypertens B 1982;1(2-3):371-83
38. Aswathkumar R, Gilvaz S. Management of severe hypertension in pregnancy: prospective comparison of labetalol vs nifedipine [abstract]. In: 49th All India Congress of Obstetrics and Gynaecology; 6 - 9 January 2006; Cochin, Kerala, India; 2006. p. 38
39. Desai BB, Swamy MK, Patil KP. A randomized controlled trial of oral nifedipine vs intravenous labetalol in acute control of blood pressure in hypertensive emergencies of pregnancy. In: 54th All India Congress of Obstetrics and Gynaecology; 5 - 9 January 2011; Cochin, Kerala, India. 2011. p. 179
40. Elatrous S, Nouira S, Ouanes BL, et al. Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. Intensive Care Med 2002;28(9):1281-6
41. Raheem IA, Saaid R, Omar SZ, Tan PC. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG 2012;119(1):78-85
42. Michael CA. Intravenous labetalol and intravenous diazoxide in severe hypertension complicating pregnancy. Aust N Z J Obstet Gynaecol 1986;26(1):26-9
43. Moore MP, Redman CWG. The treatment of hypertension in pregnancy. Curr Med Res Opin 1982;8:S39-46
44. Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003;327(7421):955-60
45. Tuffnell DJ, Jankowicz D, Lindow SW, et al. Outcomes of severe pre-eclampsia/ eclampsia in Yorkshire 1999/2003. BJOG 2005;112(7):875-80
46. Magee L, von Dadelszen P, Rey E, et al. Less-tight ver++sus Tight control of hypertension in pregnancy. New Engl J Med 2015;372(5):407-17
47. Cruickshank DJ, Campbell D, Robertson AA, MacGillivray I. Intra-uterine growth retardation and maternal labetalol treatment in a random allocation controlled study. J Obstet Gynaecol 1992;12:223-7
48. Li CY, Lao TT, Yu KM, et al. The effect of labetalol on mild pre-eclampsia. Proceedings of 7th Word Congress of Hypertension in Pregnancy; Perugia, Italy; 1990. p. 191
49. Pickles CJ, Broughton PF, Symonds EM. A randomised placebo controlled trial of labetalol in the treatment of mild to moderate pregnancy induced hypertension. Br J Obstet Gynaecol 1992;99(12):964-8
50. Sibai BM, Gonzalez AR, Mabie WC, Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol 1987;70(3 Pt 1):323-7
51. Walker JJ, Crooks A, Erwin L, Calder AA. Labetalol in pregnancyinduced hypertension: fetal and maternal effects. In: Reilly A, Symonds EM, editors. Amsterdam: 1982. p. 148-60
52. Lamming GD, Broughton PF, Symonds EM. Comparison of the alpha and beta blocking drug, labetalol, and methyl dopa in the treatment of moderate and severe pregnancy-induced hypertension. Clin Exp Hypertens 1980;2(5):865-95
53. Lardoux H, Blazquez G, Leperlier E, Gerard J. [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. Arch Mal Coeur Vaiss 1988;81(Spec No):137-40
54. Molvi SN, Mir S, Rana VS, et al. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet 2012;285(6):1553-62
55. Plouin PF, Breart G, Maillard F, et al. Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. Br J Obstet Gynaecol 1988;95(9):868-76
56. Sibai BM, Mabie WC, Shamsa F, et al. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990;162(4):960-6
57. Subhedar B, Inamdar S, Hariharan C, Subhedar S. Comparison of efficacy of labetalol and methyldopa in patients with pregnancy-induced hypertension. Int J Reprod Contracept Obstet Gynecol 2013;2(1):27-34
58. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2014;2:CD002252
59. Magee LA, von Dadelszen P, Chan S, et al. The control of hypertension in pregnancy study pilot trial. BJOG 2007;114(6):770.e13-20
60. von Dadelszen P, Ornstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet 2000;355(9198):87-92
61. von Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol Can 2002;24(12):941-5
62. El Guindy AA, Nabhan AF. A randomized trial of tight vs. less tight control of mild essential and gestational hypertension in pregnancy. J Perinat Med 2008;36(5):413-18
63. Waterman EJ, Magee LA, Lim KI, et al. Do commonly used oral antihypertensives alter fetal or neonatal heart rate characteristics? A systematic review. Hypertens Pregnancy 2004;23(2):155-69
64. Breastfeeding and the use of human milk. Pediatrics 2012;129(3):e827-41
65. Lunell NO, Kulas J, Rane A. Transfer of labetalol into amniotic fluid and breast milk in lactating women. Eur J Clin Pharmacol 1985;28(5):597-9
66. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet 1988;14(4):217-40
67. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004;114(2 Suppl 4th Report):555-76
68. Mirpuri J, Patel H, Rhee D, Crowley R. What's mom on? A case of bradycardia in a premature infant on breast milk. J Invest Med 2008;56:409
69. Ehrenstein V, Rothman KJ, Pedersen L, et al. Pregnancy-associated hypertensive disorders and adult cognitive function among Danish conscripts. Am J Epidemiol 2009;170(8):1025-31
70. Seidman DS, Laor A, Gale R, et al. Pre-eclampsia and offspring's blood pressure, cognitive ability and physical development at 17-years-of-age. Br J Obstet Gynaecol 1991;98(10):1009-14
71. Whitehouse AJ, Robinson M, Newnham JP, Pennell CE. Do hypertensive diseases of pregnancy disrupt neurocognitive development in offspring? Paediatr Perinat Epidemiol 2012;26(2):101-8
72. Chan WS, Koren G, Barrera M, et al. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy 2010;29(3):271-83
73. Pasker-de Jong PC, Zielhuis GA, van Gelder MM, et al. Antihypertensive treatment during pregnancy and functional development at primary school age in a historical cohort study. BJOG 2010;117(9):1080-6
74. Williams PJ, Morgan L. The role of genetics in pre-eclampsia and potential pharmacogenomic interventions. Pharmgenomics Pers Med 2012;5:37-51
75. Madadi P, Moretti M, Djokanovic N, et al. Guidelines for maternal codeine use during breastfeeding. Can Fam Physician 2009;55(11):1077-8
76. Cooper WO. Clinical implications of increased congenital malformations after first trimester exposures to angiotensinconverting enzyme inhibitors. J Cardiovasc Nurs 2008;23(1):20-4
77. Moretti ME, Caprara D, Drehuta I, et al. The fetal safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Obstet Gynecol Int 2012;2012:658310
78. Walfisch A, Al-maawali A, Moretti ME, et al. Teratogenicity of angiotensin converting enzyme inhibitors or receptor blockers. J Obstet Gynaecol 2011;31(6):465-72
79. Dasgupta K, Quinn RR, Zarnke KB, et al. The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2014;30(5):485-501
80. Hall DR, Odendaal HJ, Steyn DW, Smith M. Nifedipine or prazosin as a second agent to control early severe hypertension in pregnancy; a randomised controlled trial. Br J Obstet Gynaecol 2000;107:759-65
81. Bayliss H, Churchill D, Beevers M, Beevers DG. Anti-hypertensive drugs in pregnancy and fetal growth: evidence for "pharmacological programming" in the first trimester? Hypertens Pregnancy 2002;21(2):161-74
82. Cockburn J, Moar VA, Ounsted M, Redman CW. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982;1(8273):647-9
83. Bortolus R, Ricci E, Chatenoud L, Parazzini F. Nifedipine administered in pregnancy: effect on the development of children at 18 months. Br J Obstet Gynaecol 2000;107(6):792-4
84. Brown MA, Buddle ML, Farrell T, Davis GK. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol 2002;187(4):1046-50
85. Magee LA, Miremadi S, Li J, et al. Therapy with both magnesium sulfate and nifedipine does not increase the risk of serious magnesium-related maternal side effects in women with preeclampsia. Am J Obstet Gynecol 2005;193(1):153-63
86. Lactmed. Available from: http://toxnet. nlm.nih.gov/newtoxnet/lactmed.htm [Accessed 21 September 2014]
87. Lalani S, Firoz T, Magee LA, et al. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can 2013;35(3):215-23